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In humans, the most common genomic disorder is a hemizygous deletion of a 1.5–3Mb
region of chromosome 22q11.2. The resultant 22q11.2 deletion syndrome (22q11.2DS)
can affect multiple organ systems, and most notably includes cardiac, craniofacial,
and neurodevelopmental defects. Individuals with 22q11.2DS have a 20–25-fold risk of
developing schizophrenia compared to individuals from the general population, making
22q11.2DS the strongest known molecular genetic risk factor for schizophrenia. Although
the deleted region includes DGCR8, a gene coding for a miRNA processing protein, the
exact mechanism by which this deletion increases risk is unknown. Importantly, several
lines of evidence suggest that miRNAs may modulate risk for schizophrenia in other,
non-22q11.2DS populations. Here we present a theory which mechanistically explains
the link between 22q11.2DS, miRNAs, and schizophrenia risk. We outline the testable
predictions generated by this theory and present preliminary data in support of our model.
Further experimental validation of this model could provide important insights into the
etiology of both 22q11.2DS and more common forms of schizophrenia.
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BACKGROUND
Microdeletion of chromosome 22q11.2 or 22q11.2 deletion syn-
drome (22q11.2DS) (MIM #188400/#192430) is the most com-
mon human deletion syndrome with an estimated prevalence of
1 in 4000 live births (Goodship et al., 1998). Formerly known as
DiGeorge or velocardiofacial syndromes, the expression is vari-
able in severity and number of associated features (Bassett et al.,
2011). While classically these include developmental features such
as congenital cardiac and palatal anomalies, an often subtle facial
phenotype and developmental delays and/or learning difficul-
ties, later onset conditions are also commonly associated. These
include hypocalcemia and thyroid abnormalities as well as psychi-
atric illnesses (Bassett et al., 2011). Over 60% of patients develop
treatable psychiatric disorders by adulthood (Fung et al., 2010). In
particular, about one in every four adults develops schizophrenia
(Fung et al., 2010) and due to this high prevalence in 22q11.2DS
patients, the 22q11.2 region is considered to be one of the main
schizophrenia susceptibility loci in humans (Bassett and Chow,
2008; Insel, 2010).
The 22q11.2 region is flanked by low copy repeats (LCRs) with
greater than 97% DNA sequence identity. As for other genomic
disorders (Kumar, 2008), the main mechanism giving rise to the
hemizygous 22q11.2 deletion involves non-allelic homologous
recombination that results from misalignment of LCRs during
meiosis (Edelmann et al., 1999). Up to 90% of recombination
events give rise to the common 3Mb deletion (Shaikh et al.,
2000), with approximately 8% of patients having a 1.5Mb dele-
tion, nested within the proximal region of the 3Mb deletion.
Rare smaller or atypical deletions have been reported but there
is no evidence for specific genotype–phenotype correlations
(Bassett et al., 2011). Over 90% of cases are found to have a de
novo 22q11.2 deletion with the remainder found to be inher-
ited from a parent. The commonly deleted region in 22q11.2DS
encompasses approximately 45 genes and the consequences of
decreased gene dosage of multiple genes are believed to be
involved in phenotypic expression (Meechan et al., 2011). The
molecular substrates underlying the different clinical features of
22q11.2 deletion, however, are still debated. One gene of par-
ticular interest, in the proximal deletion region, is DiGeorge
Critical Region Gene 8 (DGCR8), which plays a critical role in
the biogenesis of miRNAs (Figure 1).
Multiple lines of evidence have implicated miRNAs in gen-
eral aspects of neurodevelopment, neurodegeneration, and brain
function and specifically in schizophrenia (reviewed in Beveridge
and Cairns, 2012; Mellios and Sur, 2012; Saito and Saito, 2012).
A very large genome-wide association study of over 50,000 indi-
viduals identified a SNP in miR-137 as strongly (p = 1.6×
10−11) associated with schizophrenia (Ripke et al., 2011). In
addition, five genes associated with schizophrenia (ZNF804A,
CACNA1C, TCF4, CSMD1, and C10orf26) have all been val-
idated as targets of miR-137 (Kwon et al., 2011; Kim et al.,
2012), suggesting that genes involved in schizophrenia suscepti-
bility can be affected by either cis-acting mutations at the gene
or via alterations in the miRNA regulatory system. DICER1,
another critical gene for miRNA biogenesis, has also been poten-
tially implicated in schizophrenia by a de novo CNV associated
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FIGURE 1 | Overview of miRNA processing. MicroRNAs (miRNAs)
comprise a growing class of endogenous molecules that regulate gene
expression post-transcriptionally. By binding to partially complementary
regions at the 3’ end of messenger RNAs, these approximately 22-nucleotide
single-stranded molecules direct target site recognition by the
macromolecular RNA-induced silencing complex (RISC). RISC induces
cleavage or translational repression of targeted transcripts. Mammalian
miRNA biosynthesis begins with RNA polymerase II-dependent transcription,
which yields long primary miRNA (pri-miRNA) transcripts. The pri-miRNA is
processed in the nucleus to a pre-miRNA by the Microprocesser complex,
which consists of Drosha, a member of ribonuclease III family (RNaseIII), and
DGCR8 (also known as Pasha), which contains two double-stranded RNA
binding domains and is responsible for pri-miRNA recognition. The
pre-miRNA is then exported to the cytoplasm by Exportin-5 and further
processed into a miRNA duplex by Dicer, another RNase III. One strand of
the miRNA duplex is then incorporated into the RISC.
with illness (Xu et al., 2008). Multiple suggestive level associ-
ations with schizophrenia have also been reported with SNPs
in miRNA pathway genes (Zhang et al., 2012). Numerous post-
mortem studies of miRNA expression in human brain have
reported alterations in tissue from individuals with schizophrenia
(reviewed in Beveridge and Cairns, 2012). Of particular inter-
est, Moreau et al. (2011) reported a significant overlap between
the miRNAs dysregulated in human postmortem tissue from
individual with psychotic illness and the miRNAs previously
reported dysregulated in brain tissue from a mouse model of
22q11.2DS (Stark et al., 2008). These finding support the involve-
ment of miRNAs in schizophrenia via multiple mechanisms
and suggest that there may be overlap in the specific miRNAs
involved in 22q11.2DS and non-22q11.2DS mediated cases of
schizophrenia.
THE PUZZLE
Despite the strikingly increased risk for schizophrenia in
22q11.2DS, approximately 75% of individuals with a 22q11.2
deletion do not develop schizophrenia. Other high-risk features
of this syndrome, e.g., severe congenital cardiac defects, show
comparable levels of reduced penetrance. A number of pos-
sible explanations for this variability exist, with these factors
potentially acting alone or in combination.
CHANCE VARIATION
Stochastic processes can results in individuals with identical
genetic endowments and apparently identical environmental
exposures developing along different pathways. One could imag-
ine some key cellular factor with a threshold effect on devel-
opment that is hovering right at the critical level in individuals
with 22q11.2DS. Some individuals will be fortunate enough to
have just enough of the factor to proceed down the usual devel-
opmental pathway, while others may fall just short due to ran-
dom fluctuations in expression and proceed down an alternative
pathway.
ENVIRONMENTAL FACTORS
Triggering or protective environmental factors can interact with
identical genomes to produce divergent outcomes in different
individuals. Even the intrauterine environment of twins differs,
as evidenced by frequently discordant in utero HIV transmission
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(Biggar et al., 2003). The potential divergence of environmental
exposures for an adult onset disorder such as schizophrenia would
be expected to be even greater.
VARIATIONS IN DELETION SIZE
The 22q11.2 region contains a set of low copy number repeats
that can mediate a variety of specific deletion events. Deletions
mediated by different specific LCRs will result in different sets of
genes being deleted. Even deletions that appear grossly the same
in size may exhibit some variability at the sites of the non-allelic
homologous recombination events. These small differences near
the deletion break-points may influence the expression of genes
critical for determining some of the phenotypic variability of the
syndrome. Although there is no evidence to date for this mecha-
nism, careful sequencing studies of the deletion region may shed
further light on this possibility.
VARIATIONS IN THE HEMIZYGOUS REGION OF 22q11.2
Individuals with 22q11.2DS have only a single remaining copy
of the genes in the deletion region. Any susceptibility variants
present in these genes no longer have the chance of being com-
pensated for by a non-susceptibility variant on the homolog. A
variant in PIK4CA has been associated with risk of developing
schizophrenia in individuals with 22q11.2DS, but alone is not suf-
ficient to explain the variable penetrance of schizophrenia in these
individuals (Vorstman et al., 2009). Sequencing studies of the
deletion region will also help clarify this possibility. Interestingly,
sequencing of a major congenital cardiac disease gene from the
deletion region, TBX1, did not reveal such variants for expression
of tetralogy of Fallot in 22q11.2DS (Guo et al., 2011).
VARIATIONS ELSEWHERE IN THE GENOME
A final potential source of phenotypic variability in 22q11.2DS
is genetic variation elsewhere in the genome. Such variants may
be considered genetic background effects. The importance of
genetic background on variable expressivity and penetrance is
well known from the mouse genetics literature, where the same
mutation canmanifest very differently in different strains (Linder,
2006). This background effect could be as simple as a single
modifier locus that interacts with the deletion to determine pene-
trance of schizophrenia, or it could be similar to the complicated
genetic risk proposed for non-22q11.2DS mediated schizophre-
nia, with the potential for multiple distributed liability loci acting
in concert to cause illness. The profoundly increased risk of
schizophrenia in 22q11.2DS does suggest that the non-22q11.2
genetic component for these cases of schizophrenia should be
simpler than non-deletion mediated forms of the illness, mak-
ing this an ideal subset for intensive study. Unfortunately, the
relatively rarity of 22q11.2 deletions among individuals with
schizophrenia (approximately 1% of cases of a disease that affects
approximately 1% of the population) has hampered the assembly
of the large cohorts necessary to conduct well-powered traditional
genome-wide studies.
A TWO-HIT MODEL
Canalization is a design principle wherein developmental path-
ways are stabilized to increase phenotypic reproducibility.
This helps the organism withstand genetic or environmen-
tal perturbations by providing a buffering system that confers
robustness to developmental genetic programs. Hornstein and
Shomron have proposed miRNAs as a mechanism for canaliza-
tion (Hornstein and Shomron, 2006). In this model, miRNA
regulation can compensate for variability in gene expression
and promote constant levels of protein. Canalized traits have
an increased capacity to absorb mutational variance. Specifically,
there is a decreased penalty for mutations that alter gene regula-
tion. Altered expression of transcription factors or sequence vari-
ation in cis binding sites have minimal phenotypic consequences
as the miRNA regulatory system compensates for these changes,
keeping gene expression at the required level. Because selective
pressure is reduced, such mutations may silently accumulate,
leading to a state where large numbers of cryptic variations may
be distributed throughout the population. A sudden perturbation
of the miRNA regulatory system, caused by haploinsufficiency of
a key gene in miRNA biogenesis (DGCR8), could lead to mul-
tiple previously silenced mutations suddenly having an impact
on the organism (Figure 2). The expected underlying population
heterogeneity in these accumulated regulatory mutations could
manifest as a high degree of variability in the specific phenotypic
profile seen in individuals with DGCR8 haploinsufficiency.
DGCR8 is an essential component of the canonical miRNA
biogenesis pathway. A non-canonical processing pathway also
exits (Babiarz et al., 2008), with mouse knockout studies suggest-
ing that the brain is particularly enriched for these non-canonical
miRNAs as compared to other tissues (Babiarz et al., 2011).
A mouse model of DGCR8 haploinsufficiency has also demon-
strated that not all miRNAs are equally affected by reduced
DGCR8 levels; despite reductions of DGCR8 transcript abun-
dance to approximately 60% of wild type levels, only 22% of
maturemiRNAs assayed exhibited significantly decreased levels in
either prefrontal cortex or hippocampus in the haploinsufficient
mice (Stark et al., 2008).
A TESTABLE HYPOTHESIS
If loss of miRNA silencing of multiple regulatory mutations con-
tributes to the risk of developing schizophrenia in 22q11.2DS,
then one would expect these mutation to occur more frequently
in genes regulated by the miRNAs most impacted by DGCR8
haploinsufficiency. Even if tested in a relatively small (by genome-
wide association study standards) sample, one would expect to see
a pattern of enrichment of association findings to SNPs in or near
genes regulated by the 22q11.2DS altered miRNAs. We sought to
test this hypothesis using data from a set of 95 families with a
22q11.2DS proband.
EXPERIMENT I—GENOME-WIDE ASSOCIATION STUDY OF
SCHIZOPHRENIA IN 22q11.2DS
The first experiment in testing our hypothesis was to conduct
a GWAS of schizophrenia in 22q11.2DS. To protect against the
effects of population stratification, we chose a family based asso-
ciation design. Adults with 22q11.2DS, followed at the Clinical
Genetics Research Program, Centre for Addiction and Mental
Health (CAMH) at the University of Toronto, Canada, and their
families, were studied. Participants provided written informed
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FIGURE 2 | Two-hit model of schizophrenia in 22q11.2DS. Mutations that
are compensated for by an intact miRNA regulatory system can silently
accumulate within individuals, with little selective pressure acting to remove
them from the population. Deletion of 22q11.2 results in haploinsufficiency of
DCGR8, a key gene involved in miRNA biogenesis. The resulting decrease in
levels of certain miRNAs results in multiple regulatory mutations
simultaneously exerting deleterious effects on the individual, resulting in
schizophrenia or other serious abnormalities characteristic of 22q11.2DS.
consent, and the study was approved by the Research Ethics
Boards of the University of Toronto, CAMH, and University
Health Network. Three hundred and seventeen subjects were
included in the study. Comprehensive medical, psychiatric, and
family history data were available for all subjects. Experienced
psychiatrists provided lifetime DSM-IV psychiatric diagnoses
using standard methods, as previously described (Bassett et al.,
2007). These individuals comprised 95 families, each with an
adult proband confirmed to have a chromosome 22q11.2 dele-
tion by standard methods using metaphase chromosomes from
peripheral blood lymphocytes and FISH techniques using a
probe, most commonly TUPLE1 (Vysis) or N25 (ONCOR), from
the commonly deleted 22q11.2 region (Driscoll et al., 1993).
Forty-eight of the 22q11DS probands (26 female and 22 male)
were diagnosed with schizophrenia or schizoaffective disorder,
while psychotic illness was excluded in the remaining 47 22q11DS
probands (28 female and 19 male). Of the 222 additional fam-
ily members, five (four parents and a half-sibling) also had
22q11.2DS but no psychotic illness; four (two parents and two
siblings) were also diagnosed with schizophrenia but did not have
22q11.2DS.
All subjects with available high-quality DNA samples
(n = 244) were genotyped on Affymetrix 250K Nsp SNP arrays
at The Centre for Applied Genomics at the University of Toronto.
Genotypes for all CEL files were processed as a single batch using
Affymetrix APT software, version 1.10.0. All samples used for
further analysis had <5% missing data (n = 238). All persons
within any pedigree with a detected Mendel error were set to
zero for the marker with the error. SNPs were further excluded
from all subjects for >2% missingness or deviations from
Hardy–Weinberg equilibrium that were significant at p < 0.0001.
After cleaning, 221,996 SNPs remained for analysis.
Association analysis was conducted using the software pack-
age KELVIN 2.4.0, which implements the posterior probability
of linkage (PPL) class of models for measuring the strength of
genetic evidence (Vieland et al., 2011b). The PPL was initially
developed as a linkage analysis method (PPL originally stood for
posterior probability of linkage, but now is used to refer to the
class of related measures), based upon an acting single-locus like-
lihood allowing for within-sample heterogeneity. All parameters
of the trait model are integrated out of the PPL using simple
model averaging, allowing for testing of dominant, recessive, and
additive models without the inflationary effects of multiple test-
ing or parameter maximization. The analysis framework is quite
flexible, and many additional extensions have been implemented
such as analysis of linkage disequilibrium, quantitative traits, lia-
bility classes, imprinting, sex specific recombination rates, and
epistasis (Bartlett and Vieland, 2007; Huang et al., 2007; Huang
and Vieland, 2010; Vieland et al., 2011a). Importantly, the PPL
accumulates evidence against linkage or association as well as in
favor of it. The PPL is on the probability scale, making its inter-
pretation straightforward. As a measure of statistical evidence,
and not a decision-making procedure, there are no associated
“significance levels” and it is not interpreted in terms of associ-
ated error probabilities nor corrected for multiple testing (Royall,
1997; Vieland and Hodge, 1998; Vieland, 2006).
We chose this analysis approach for two important reasons.
First, our study design is complex and we required an analy-
sis approach that could appropriately incorporate all available
data into the analysis. While our study fundamentally has a
family based association design, it also has elements of a case-
control design, with half of the 22q11.2DS probands affected
with schizophrenia and half not. We also needed to be able to
appropriately model two different clinical elements of interest,
22q11.2 deletion status and schizophrenia status, both of which
are present in some of the first degree relatives. Our hypothe-
sis is that mutations segregating within these pedigrees have a
greater impact on causing disease in the individuals with 22q11.2
deletions. This led us to model schizophrenia as the primary cat-
egorical phenotype of interest for association analysis and model
22q11.2 deletion status as a liability class. In this type of model,
individuals with the deletion would be expected to have higher
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penetrance of schizophrenia with a given risk allele at a suscep-
tibility locus when compared to relatives without the deletion
but carrying the same risk allele. KELVIN’s flexibility allowed
our entire sample to be analyzed simultaneously, incorporat-
ing 22q11.2 deletion status as a liability class while testing for
association to schizophrenia.
The second important reason for using the PPL framework for
our analysis was the desire to use a method that would disam-
biguate strength of evidence for or against association from low
power due to the relatively small size of our sample. The PPL
provides a measure of strength of evidence for or against asso-
ciation. Beginning with a given prior probability of association,
KELVIN calculates the posterior probability of association based
on the provided sample data. If the sample is providing evidence
against association, the posterior probability will be lower than
the prior probability. If the sample is giving evidence supporting
association, the posterior probability will be higher than the prior.
The magnitude of the change, up or down, can further be used to
determine the strength of the evidence and rank order findings in
terms of likelihood of association.
The Affymetrix array data were first used to confirm that all
subjects with 22q11.2DS had deletions that included DGCR8.
Next, the 221,996 SNPs passing our quality control were tested for
association. Of these, 9191 were uninformative. Of the remain-
ing SNPs, 198,100 (93%) gave evidence against association, while
only 14,705 (7%) provided any evidence for association. Given
the small size of the sample (95 small pedigrees), we did not
expect to detect compelling evidence for association. Starting
from a prior probability of 0.04%, the maximum posterior prob-
ability of association was 1.7%, a large increase from the prior but
still within the range of what might be seen by chance in a full
GWAS. Despite the small magnitude of evidence for association
in the best supported SNPs and the expectation that some of these
findings were due to chance allele segregations, we reasoned that
these top SNPs should be enriched for real association signals. We
tested this possibility by a further application of our hypothesis of
miRNA mediated risk for schizophrenia in 22q11.2DS.
EXPERIMENT II—TEST FOR miRNA TARGET ENRICHMENT
IN 22q11.2DS SCHIZOPHRENIA
The second experiment sought to correlate our GWAS results
with miRNA data from two experimental sources. The work of
Stark et al. had demonstrated that the levels of some, but not
all, miRNAs are significantly decreased in the brains of mice
haploinsufficient for DGCR8 (Stark et al., 2008). Since a list of
miRNAs decreased in the brains of humans with 22q11.2DS is
not currently available, we began with the list from the mouse
model as the best available data, recognizing that noise would
undoubtedly be introduced into our analysis by this cross-species
approach. The 65 mouse miRNAs reported as downregulated in
either prefrontal cortex or hippocampus (Stark et al., 2008) were
mapped to their human orthologs and used to query starBase
v2.1 (Yang et al., 2011) to determine a list of human genes impli-
cated by two or more CLIP-seq experiments to interact with the
miRNAs of interest (Hafner et al., 2010). Overall, 2860 genes
were identified as potentially interacting with one or more of the
miRNA of interest. Of these, 1047 were predicted to interact with
Table 1 | Distribution of CLIP-seq interactions with miRNAs of
interest.









a single miRNA with the remaining genes predicted to interact
with between 2 and 34 of the miRNAs investigated (Table 1).
Before we could compare this list of genes to our GWAS results,
we needed to establish a method for identifying genes that might
be regulated by an associated SNP. While cis-acting regulatory
sequences can act on genes located over 1Mb away, the sequences
that act over the greatest distances tend to be found in gene-poor
regions (reviewed in Kleinjan and Coutinho, 2009), suggesting
that the physical extent of a candidate region surrounding an
LD signal can be modulated by the gene density of the area. We
therefore developed an algorithm to map SNPs to potential gene
targets based on local gene density. The genomic locations of all
RefSeq genes mapped to NCBI Build 36.1 of the human genome
were downloaded from the UCSC genome browser (Lander et al.,
2001; Kent et al., 2002; Fujita et al., 2011). We then used a four-
tiered size approach for searching for potential gene targets. We
began by identifying all genes within 25 Kb of a SNP of inter-
est. If no genes were identified, the search window was expanded
to 250Kb on either side of the SNP. If no genes were identi-
fied at that step, the window was next expanded to 500Kb and
finally to 1Mb on either side of the gene. This strategy allows
for identification of distant genes from gene-poor regions while
limiting the number of genes identified from gene-dense regions.
It is important to note, however, that regardless of the inter-
val used, genes are selected purely on the basis of distance from
the SNP of interest and all genes within the given window will
be identified as potentially regulated by this SNP. This is a very
simplistic mapping procedure and even in cases where a SNP of
interest actually does have a regulatory function, our algorithm is
expected to identify the actual target of that regulatory SNP along
with other nearby, but not necessarily regulated, genes. So only
some subset of the genes on this list is expected to be of actual
interest.
From the 14,705 SNPs producing some positive evidence
of association in the GWAS, we arbitrarily selected the 0.5%
(73 SNPs) giving the strongest evidence for further analysis. Using
the algorithm described above, this set of SNPs identified a set
of 72 genes as potential regulatory targets based on location.
Of those 72 genes, 12 (17%) had been identified in starBase as
potential targets of two or more of the miRNAs observed to be
decreased in the DGCR8 haploinsufficient mice. To determine
if this represented enrichment over what would be expected by
chance, we conducted a simulation study.
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The distribution of the Affymetrix 250K SNPs across genes and
the genome is neither perfectly uniform nor random. Similarly,
the top association signals are not randomly distributed across the
Affymetrix SNPs, with some grouping of positive signals among
SNPs in strong linkage disequilibrium with each other. To try
to best maintain any effects due to the actual location of the
Affymetrix SNPs in the genome and the relative clustering of
association signals within nearby SNPs, we devised the following
simulation scheme. The pattern of the 73 positive SNPs from the
analysis of our real data among the total 221,996 SNPs passing
our quality control was defined. For each simulated dataset, this
pattern was offset by a random number between 1 and 221,966
(Figure 3). This produced a simulated dataset with the same
degree of clustering of SNPs as the real data, but with a differ-
ent specific set of 73 Affymetrix 250K SNPs selected as targets.
These SNPs would then be mapped to genes following the same
algorithm that was used for the real data.
Ten thousand simulated datasets were generated by this pro-
cedure. The mean number of genes identified by our mapping
algorithm in the simulated datasets was 73.0 (s.d. = 11.8), com-
pared to 72 in our real data, suggesting that the simulation
procedure successfully generated comparably sized sets of genes.
However, among the simulated datasets, only an average of 9.3%
of the genes were identified in starBase as potential targets of
two or more of the miRNAs observed to be decreased in the
DGCR8 haploinsufficient mice, compared to the 17% observed in
the real data set. Based on the distribution of results seen in our
simulated data sets, the results observed in the real data set repre-
sent a substantial enrichment of genes predicted to be regulated
by the miRNAs most disrupted by DGCR8 haploinsufficiency,
significant at p = 0.03. This is the result that was predicted by
our hypothesis.
LIMITATIONS OF THIS STUDY
The results of these preliminary experiments support our model
that the increased risk of schizophrenia in individuals with
22q11.2DS is at least partially due to a loss of miRNA com-
pensation for SNP variants that alter regulation of susceptibility
genes. As predicted by our model, our experimental results pro-
duced statistically significant enrichment in genes likely to be
regulated by the miRNAs decreased byDCGR8 haploinsufficiency
over what would be expected by chance. This result is particu-
larly striking given the number of significant limitations of this
study.
First, we used data from DGCR8 haploinsufficient mice (Stark
et al., 2008) as the source of the list of themost disruptedmiRNAs.
It is possible that the levels of the orthologous miRNAs will not
all be similarly altered in humans with 22q11.2DS. Furthermore,
the effects of 22q11.2DS on primate and human specific miRNAs
will not be informed by the murine model. Therefore, our start-
ing list of miRNAs of interest is incomplete at best but may also
contain miRNAs that are not significantly decreased in humans
with 22q11.2DS. Ideally, we would start with a list of altered miR-
NAs obtained through study of human brain tissue from subjects
with 22q11.2DS. Given the relative rarity of this syndrome and
the general challenges in obtaining human post-mortem brain
tissue suitable for gene expression studies, a sizable collection
of such tissues will likely be difficult to obtain. Perhaps more
logistically feasible would be to use neural tissue derived from
induced pluripotent stem cells (iPSCs) made from individuals
with 22q11.2DS, although such a derived cell population might
include experimentally induced genetic or epigenetic changes.
Even profiling of blood samples from individuals with 22q11.2
DS might provide some valuable insights into alterations of pri-
mate and human specific miRNAs. Our studies clearly need to
FIGURE 3 | Scheme for simulation to evaluate significance of
experimental results. The pattern of the positive SNPs from the original data
among the total SNPs passing our quality control was defined. For each
simulated dataset, this pattern was offset by a random number between 1
and number of SNPs in the original data. In this illustration of the simulation
scheme, 19 SNPs are modeled, with the red ovals indicating SNPs of
interest. The top line represents the original data. The next two lines
represent simulated datasets with offsets of two and five SNPs, respectively.
The last line represents a simulated dataset with an offset of ten; in this case
the rightmost positive SNPs would be moved off the right end of the set, so
it is instead wrapped around to the start of the set, at the position indicated
by the yellow oval. For the genome-wide simulation, all chromosomes were
laid end-to-end in numerical order to create one continuous array of 221,996
SNPs.
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be repeated with a list of miRNAs experimentally derived from
human source tissue.
Second, we chose to use CLIP-seq data, rather than bioinfor-
matic prediction, to identify potential targets of the miRNAs of
interest. CLIP-seq data have the advantage of identifying miRNA
targets with better specificity than bioinformatic approaches
(Chi et al., 2009; Zisoulis et al., 2010). For example, query-
ing the miRWalk database (Dweep et al., 2011) for predicted
targets of the miRNAs of interest using the default setting (tar-
get identification by miRanda, miRDB, miRWalk, RNA22, and
TargetScan) identifies 10,037 genes predicted to be targets of
one or more of the miRNAs of interest, 3.5 times as many
as were identified by the available CLIP-seq data. This larger
dataset appears to have a worse signal-to-noise ratio than the
CLIP-seq data, as repeating our experiments using this very
large set of potential target genes failed to produce signifi-
cant results. More stringent bioinformatic prediction procedures
might well perform better. However, the use of CLIP-seq data
also has limitations. As an experimentally based approach, the
discovered interactions will be limited by the gene expression
profiles of the cells that are interrogated. The currently avail-
able human CLIP-seq data are still somewhat limited, but as
more tissue types are investigated the comprehensiveness of
the interactions catalogued will increase and be of even greater
value.
Third, we used a sample for this study that is too small to
be likely to be able to produce compelling evidence in sup-
port of association in the context of a GWAS. While the PPL
analysis framework has been demonstrated to have a superior
signal-to-noise ratio when compared to other common anal-
ysis methods (Huang and Vieland, 2001; Vieland et al., 2001;
Logue et al., 2005), the low score threshold for the SNPs inves-
tigated in this study clearly overlaps the range of scores that
could be seen by chance in a GWAS. Therefore, we expect that
some of the SNPs of interest represent false positives. As a group,
however, we expect the SNPs of interest to be enriched for
true association signals when compared to comparable random
sets of SNPs. While subjects with 22q11.2DS are relatively rare,
the importance of this syndrome as a model for studying the
neurodevelopmental trajectory of schizophrenia has been rec-
ognized (Insel, 2010), leading to a new international focus on
recruiting such individuals for genetic studies. Larger cohorts
will have great power to separate real signals from background
noise.
Fourth, we implemented a very simple SNP-to-gene map-
ping algorithm that identified multiple genes surrounding each
associated SNP based solely on physical position. While our
procedure used variable size intervals to limit the number
of genes identified from the more gene-dense regions of the
genome, our algorithm will typically return sets of genes for
each SNP of interest, with only a fraction of the identified
genes expected to be the target of a SNP with regulatory func-
tion. Additional layers of bioinformatic analysis could be added
to attempt to further predict the potential regulatory function
of the SNPs of interest (or SNPs in strong linkage disequi-
librium with them). Functional validation studies of putative
regulatory SNPs could also be of utility. Another resource for
potentially identifying the regulatory targets of SNPs of inter-
est would be gene expression profiles from individuals with
22q11.2DS. Our hypothesis is that deleterious regulatory muta-
tions are uncovered by damage to the miRNA regulatory system.
Therefore, we would expect to see increased expression of the
gene targets of the decreased miRNAs. Expression data could
be used to further refine the list of putative targets of SNPs of
interest.
Fifth, we conducted these experiments using relatively low-
density SNP data from Affymetrix 250K NSP arrays. It is quite
likely that important signals were missed due to the low SNP
density. While this initial study has produced intriguing results,
additional studies using a higher density SNP array will be neces-
sary to more comprehensively search the genome for association
signals.
ADDITIONAL CONSIDERATIONS
While we have focused this study on the presence or absence of
schizophrenia in individuals with 22q11.2DS, this model could
also explain the variability in multiple symptoms of this syn-
drome. Under the canalization model of Hornstein and Shomron
(2006), multiple regulatory mutations can accumulate in the pop-
ulation, free from selective pressure, in the presence of an intact
miRNA regulatory system. One would expect the specific dis-
tribution of compensated mutations to differ from individual
to individual, due to chance segregation of the various deleteri-
ous alleles in the population. The striking phenotypic variability
of individuals with 22q11.2DS could be due, in part, to the
underlying heterogeneity of regulatory mutations that are sud-
denly uncovered by DGCR8 haploinsufficiency. One could repeat
our experiments with additional phenotypes, such as cardiac
malformations, to further test this hypothesis.
Identification and validation of the specific gene targets
leading to schizophrenia in the setting of altered miRNAs in
22q11.2DS could provide valuable new insights into this disor-
der. These genes could represent novel targets for pharmacologic
intervention, and it is possible that targeting one or a small num-
ber of them could be therapeutically effective. Alternatively, it
might be possible to pharmacologically manipulate the miRNA
regulatory system more globally. For example, the pri-miRNA
processing activity of DGCR8 has been linked to levels of ferric
heme, leading to the suggestion that manipulation of the intra-
cellular environment with heme derivatives might have utility in
increasing DGCR8 activity (Barr et al., 2012). Such a therapy
would directly address the molecular lesion caused by DGCR8
haploinsufficiency.
While 22q11.2DS contributes to a minority of all cases of
schizophrenia, there may well be mechanistic overlap with non-
22q11.2DS cases of illness. Post-mortem analysis of human brain
tissue has indicated a significant overlap in the miRNAs dysreg-
ulated in non-22q11.2DS individuals with psychotic illness and
those depleted in a mouse model of 22q11.2DS (Stark et al.,
2008; Moreau et al., 2011), suggesting the potential for shared
mechanisms between etiologically different forms of schizophre-
nia. Further understanding of 22q11.2DS may well inform our
global understanding of the causes, and potential treatment, of all
schizophrenia.
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